These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 16550756

  • 1. Reply to Yang et al. Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin receptor blocker (ARB) in pediatric patients with IgA nephropathy.
    Mandal A.
    Clin Nephrol; 2006 Mar; 65(3):227; author reply 227-8. PubMed ID: 16550756
    [No Abstract] [Full Text] [Related]

  • 2. Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.
    Nakamura T, Inoue T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Node K.
    Am J Hypertens; 2007 Nov; 20(11):1195-201. PubMed ID: 17954367
    [Abstract] [Full Text] [Related]

  • 3. Does angiotensin blockade influence graft outcome in renal transplant recipients with IgA nephropathy?
    Courtney AE, McNamee PT, Nelson WE, Maxwell AP.
    Nephrol Dial Transplant; 2006 Dec; 21(12):3550-4. PubMed ID: 16968729
    [Abstract] [Full Text] [Related]

  • 4. Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy.
    Yang Y, Ohta K, Shimizu M, Nakai A, Kasahara Y, Yachie A, Koizumi S.
    Clin Nephrol; 2005 Jul; 64(1):35-40. PubMed ID: 16047643
    [Abstract] [Full Text] [Related]

  • 5. [Therapeutic effects of RAS inhibitor in IgA nephropathy].
    Kashihara N.
    Nihon Jinzo Gakkai Shi; 2008 Jul; 50(4):473-7. PubMed ID: 18546877
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. IgA nephritis--ACE inhibitors, steroids etc?
    Wardle EN.
    Nephrol Dial Transplant; 2007 Jun; 22(6):1785; author reply 1785. PubMed ID: 17403702
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker adherence in patients with primary versus secondary diagnosis of heart failure.
    Brackbill ML, Bashaw-Keaton R, Sytsma CS.
    Am J Manag Care; 2007 Oct; 13(10):568-70. PubMed ID: 17927461
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy.
    Horita Y, Taura K, Taguchi T, Furusu A, Kohno S.
    Nephrology (Carlton); 2006 Oct; 11(5):462-6. PubMed ID: 17014562
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.